tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2017 Jan 24:1-12. doi: 10.1080/21645515.2016.1256928. [Epub ahead of print]
[h=1]Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.[/h] Jamotte A[SUP]1[/SUP], Clay E[SUP]1[/SUP], Macabeo B[SUP]2[/SUP], Caicedo A[SUP]3[/SUP], Lopez JG[SUP]4[/SUP], Bricks L[SUP]5[/SUP], Romero Prada M[SUP]6[/SUP], Marrugo R[SUP]6[/SUP], Alfonso P[SUP]6[/SUP], Moreno Ar?valo B[SUP]7[/SUP], Franco D[SUP]7[/SUP], Garcia Diaz L[SUP]8[/SUP], Isaza de Molto Y[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin American countries. However, the circulation of 2 B lineages (Victoria and Yamagata) and difficulties in predicting the predominating lineage have led to the development of quadrivalent influenza vaccines (QIV), including both B lineages. Thus, the objective was to estimate the public health impact and influenza-related costs if QIV would have been used instead of TIV in 3 Latin American countries. We used a static model over the seasons 2010-2014 in Brazil, 2007-2014 in Colombia and 2006-2014 in Panama, focusing on population groups targeted by local vaccination recommendations: young children, adults with risk factors and the elderly. In Brazil, between 2010 and 2014, using QIV instead of TIV would have avoided US$ 6,200 per 100,000 person-years in societal costs, based on 168 influenza cases, 89 consultations, 3.2 hospitalizations and 0.38 deaths per 100,000 person-years. In Colombia and Panama, these would have ranged from US$ 1,000 to 12,700 (based on 34 cases, 13-25 consultations, 0.6-8.9 hospitalizations and 0.04-1.74 deaths) and from US$ 3,000 to 33,700 (based on 113 cases, 55-82 consultations, 0.5-27.8 hospitalizations and 0.08-6.87 deaths) per 100,000 person-years, respectively. Overall, the broader protection offered by QIV would have reduced the influenza humanistic and economic burden in the 3 countries. Despite the lack of local data leading to several extrapolations, this study is the first to give quantitative estimates of the potential benefits of QIV in Latin America.
[h=4]KEYWORDS:[/h] Brazil; Colombia; Latin America; Panama; benefit; cost; influenza; public health; quadrivalent; vaccine
PMID: 28118092 DOI: 10.1080/21645515.2016.1256928
[PubMed - as supplied by publisher]
[h=1]Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.[/h] Jamotte A[SUP]1[/SUP], Clay E[SUP]1[/SUP], Macabeo B[SUP]2[/SUP], Caicedo A[SUP]3[/SUP], Lopez JG[SUP]4[/SUP], Bricks L[SUP]5[/SUP], Romero Prada M[SUP]6[/SUP], Marrugo R[SUP]6[/SUP], Alfonso P[SUP]6[/SUP], Moreno Ar?valo B[SUP]7[/SUP], Franco D[SUP]7[/SUP], Garcia Diaz L[SUP]8[/SUP], Isaza de Molto Y[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin American countries. However, the circulation of 2 B lineages (Victoria and Yamagata) and difficulties in predicting the predominating lineage have led to the development of quadrivalent influenza vaccines (QIV), including both B lineages. Thus, the objective was to estimate the public health impact and influenza-related costs if QIV would have been used instead of TIV in 3 Latin American countries. We used a static model over the seasons 2010-2014 in Brazil, 2007-2014 in Colombia and 2006-2014 in Panama, focusing on population groups targeted by local vaccination recommendations: young children, adults with risk factors and the elderly. In Brazil, between 2010 and 2014, using QIV instead of TIV would have avoided US$ 6,200 per 100,000 person-years in societal costs, based on 168 influenza cases, 89 consultations, 3.2 hospitalizations and 0.38 deaths per 100,000 person-years. In Colombia and Panama, these would have ranged from US$ 1,000 to 12,700 (based on 34 cases, 13-25 consultations, 0.6-8.9 hospitalizations and 0.04-1.74 deaths) and from US$ 3,000 to 33,700 (based on 113 cases, 55-82 consultations, 0.5-27.8 hospitalizations and 0.08-6.87 deaths) per 100,000 person-years, respectively. Overall, the broader protection offered by QIV would have reduced the influenza humanistic and economic burden in the 3 countries. Despite the lack of local data leading to several extrapolations, this study is the first to give quantitative estimates of the potential benefits of QIV in Latin America.
[h=4]KEYWORDS:[/h] Brazil; Colombia; Latin America; Panama; benefit; cost; influenza; public health; quadrivalent; vaccine
PMID: 28118092 DOI: 10.1080/21645515.2016.1256928
[PubMed - as supplied by publisher]